Candel Therapeutics Stock News

Investment analysts at BMO Capital Markets assumed coverage on shares of Candel Therapeutics (NASDAQ:CADL) in a research note issued on Thursday, Price Targets.com reports. The firm set an outperform rating and a $18.00 price target on the stock. BMO Capital Markets target price suggests a potential upside of 65.59% from the stocks current price. A []

Candel Therapeutics (NASDAQ:CADL) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The companys product pipeline includes CAN-2409 and CAN-3110. []

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today anno

NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today anno

NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today anno